Relmada Therapeutics (RLMD) Net Equity Issued and Repurchased (2012 - 2022)

Relmada Therapeutics (RLMD) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $13.1 million in Q2 2022.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $13.1 million in Q2 2022; TTM through Dec 2022 was $42.7 million, a 73.48% decrease from a year earlier, with the FY2025 full-year figure at $93.6 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q2 2022 stood at $13.1 million, down from $29.6 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for RLMD reached as high as $161.2 million in Q4 2021 and fell as low as -$8.2 million in Q4 2018.
• Historically, Net Equity Issued and Repurchased has averaged $20.2 million across 5 years, with a median of $1.7 million in 2019.
• Across the five-year window, Net Equity Issued and Repurchased plunged 100.29% in 2020 and soared 646222.49% in 2021, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$8.2 million in 2018, then surged by 262.89% to $13.4 million in 2019, then plunged by 100.19% to -$24953.0 in 2020, then surged by 646222.49% to $161.2 million in 2021, then plunged by 91.85% to $13.1 million in 2022.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $13.1 million in Q2 2022, $29.6 million in Q1 2022, and $161.2 million in Q4 2021.